A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Amneal Pharmaceuticals (AMRX) announced the FDA approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which references Janssen’s ...

Pharma major Lupin Ltd on Wednesday said it has received approval from the US health regulator for its generic version of risperidone for extended-release injectable suspension, used in the treatment ...

Out of 47 children who were screened, 40 patients were randomized into one of two groups. The reasons for the drop of patients in the two groups are displayed in Figure 1. The number of boys in the ...